UK government launches 10-year health plan for a future-ready NHS England powered by data and innovation

With its 10‑Year Health Plan, the UK government is positioning the National Health Service (NHS) as a global leader in health innovation – reinforcing three core shifts and embedding life sciences, digital tools, and regulatory agility at the heart of transformation.

Following Lord Darzi’s 2024 review of the NHS in England, the UK government has unveiled its ambitious 10 Year Health Plan for England, with the goal of building a future-ready health service. Shaped with input from the public, healthcare staff, and partner organizations, the 168-page plan outlines three major shifts aiming to, “create a new model of care, fit for the future.”

The plan's first major goal focuses on moving care from hospitals into the community. This aims to enable more local access to services through Neighborhood Health Centers and expanded home-based care options. Secondly, the strategy details a transition from analogue to digital. By leveraging the NHS' data assets and infrastructure, the objective is to create an app-enabled system for patients and reduce administrative burdens for staff. Finally, the plan emphasizes a shift from sickness to prevention through a proactive approach to health, focusing on early intervention and promoting healthier choices.

A core pillar of this transformation is embedding life sciences innovation into healthcare delivery. As the government notes:

“Our aim is to be in the driving seat of the biggest industrial revolution since the 19th century as we harness technology to create a new model of care in the NHS. We will use the UK’s competitive edge – NHS data, life sciences prowess, world-leading universities – to lead the world on the innovation that will most accelerate reform.”

This ambition to position the NHS as a global leader in healthcare technology will leverage data, AI, genomics, wearables, and robotics. These five transformative technologies are expected to enable personalized care, improve outcomes, and strengthen financial sustainability, while also stimulating innovation and accelerating adoption.

Central to this vision is the Health Data Research Service (HDRS), which will unify diverse patient health records, including genomic data and wearable insights, into a single secure system. De-identified data will support research, innovation, and early detection, with the potential to attract investment and reinforce the UK’s position in health data science.

AI will accelerate drug discovery, streamline diagnostics, and ease administrative burdens. By 2027, validated AI tools will be deployed NHS-wide, with full integration into clinical pathways by 2035. Genomics initiatives, including Our Future Health and large-scale genome sequencing studies, will support predictive and preventive care. Wearables and biosensors will enable real-time health monitoring, with remote cardiovascular disease management set to become standard by 2028. Robotics will enhance surgical precision and automate pharmacy systems, improving efficiency.

Crucially, the plan acknowledges that innovation must be underpinned by robust operational foundations. “We will only lead the world if we get the basics right,” the government states. The Medicines and Healthcare products Regulatory Agency (MHRA) will adopt a pro-innovation regulatory approach, balancing safety with faster market access for new products. From April 2026, MHRA and the National Institute for Health and Care Excellence (NICE) will launch a joint process with shared scientific advice to accelerate approvals and reduce administrative burdens. Clinical trial reforms will cut set-up times and position the UK as a competitive hub for research.

To further support adoption and more timely access to new innovations, a new ‘innovator passport’ will be introduced by 2026. Once an innovation has been robustly assessed by one NHS organization, others will no longer require repeated evaluations. A presumption of adoption will also apply for innovations demonstrating cost-neutral, step-change improvements in care quality. Additionally, the creation of a Single National Formulary for medicines within 2 years will replace local formularies that currently create variation in access. A new oversight board, supported by NICE, will sequence products based on clinical and cost effectiveness while allowing prescribers clinical autonomy within NICE guidance. These measures aim to ensure rapid and equitable uptake of effective treatments, while reducing duplication and inefficiency across the NHS